Regenerative Medicine

Celyad licenses technology to Novartis

Belgium-based Celyad SA, which used to go by the name of Cardio3 BioSciences SA, has secured a non-exclusive licensing agreement with Novartis giving the Swiss company rights to US patents for the production of allogeneic CAR T cells.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Adaptimmune funded through to late 2019

Following share offerings in March and April that raised a net $103.2 million, Adaptimmune Therapeutics Plc has sufficient liquidity to fund operations through to late 2019, according to the company’s first-quarter results.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Immunocore identifies new lead compound

The Oxford, UK oncology company Immunocore Ltd has identified a lead compound in its second discovery collaboration with GlaxoSmithKline Plc which is expected to have potential for treating triple negative breast cancers, oesophageal, gastric and ovarian cancers.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Takeda takes option on GammaDelta

Less than a year after its founding, GammaDelta Therapeutics Ltd has received an investment from Takeda Pharmaceutical Company Ltd, which sees promise in the UK company’s T cell platform as a source for new immunotherapies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Pfizer in gene therapy deal

Pfizer Inc has expanded its portfolio of gene therapy assets following a licensing deal with Sangamo Therapeutics Inc giving it exclusive rights to a preclinical product for haemophilia A, a bleeding disorder caused by the lack of clotting factor VIII.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

ReNeuron resets clinical priorities

ReNeuron Plc has decided to put priority on bringing its cell therapy for stroke into Phase 3 and expand an early-stage programme in ophthalmology as part of a portfolio review that took into account recent clinical data and a manufacturing breakthrough.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Cold chain technology deal

GE Healthcare has expanded its capacity for industralising cell therapies with the acquisition of Asymptote Ltd, a UK consultancy with technology for simplifying the freezing of cells intended as therapies, and thawing them before their use in patients.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Meeting Report: Opportunities in cell and gene therapy

The opportunities for commercialising cell and gene therapies appeared relatively bright as the first quarter drew to a close, helped by new finance and the prospective approval of the first cancer products made from engineered T cells.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Spain

Adaptimmune raises $61.8 million to progress TCR products

Adaptimmune Therapeutics Plc has raised $61.8 million, net of expenses, in a public offering of its American Depositary Shares (ADSs) to advance its T cell receptor products for cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Cell Medica raises £60 million in Series C round

Cell Medica Ltd has closed a £60 million Series C financing round to support its cell therapy platforms. The financing was announced not long after the company received a fast track designation from the US Food and Drug Administration for its lead oncology product baltaleucel-T.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Syndicate content